Taiho Obtains Taiwanese Approval For TS One For Gastric Cancer
This article was originally published in PharmAsia News
Executive Summary
Taiwan's drug regulators approved Taiho Pharmaceutical's TS One capsule for gastric cancer adjunct therapy after surgery
Taiwan's drug regulators approved Taiho Pharmaceutical's TS One capsule for gastric cancer adjunct therapy after surgery. Taiwan is the fifth market in Asia outside of Japan to approve the cancer drug, after South Korea, China and Singapore. Taiho plans to market the drug next month through local firm TTY Biopharm. Since its 1999 approval in Japan, TS One has obtained approval for seven kinds of cancers, including gastric and colorectal cancer. Besides gastric cancer, TS One is also being developed in Taiwan to treat lung and colorectal cancer. (Click here for more - Japanese language) "Taiho Pharmaceutical Cancer Drug Obtains Taiwanese Approval" - Chemical Daily (8/23/2010) |